文献速递胸部肿瘤

卡铂与顺铂治疗小细胞肺癌生存结局及COVID-19对铂类选择影响的荷兰全国登记研究

Survival outcomes with carboplatin versus cisplatin and the impact of COVID-19 on platinum choice: A nationwide Netherlands registry study in small cell lung cancer patients (CACIS).
PubMed 文献 · Eur J Cancer · 2025-10-02

该研究基于荷兰癌症登记数据,分析2018–2023年一线铂类治疗局限期(LS-SCLC)和广泛期(ES-SCLC)小细胞肺癌患者。疫情期间卡铂季度使用率在LS-SCLC和ES-SCLC分别达81%和90%;单变量分析卡铂总生存较短,但多变量校正后无显著差异。

要点

  • 多变量校正后卡铂与顺铂在LS-SCLC和ES-SCLC的总生存无显著差异。
  • 疫情期间卡铂使用率显著上升,LS-SCLC达81%、ES-SCLC达90%。
  • 卡铂血液学毒性更高,顺铂非血液学毒性更多。

核心结论

  • 多变量校正后卡铂与顺铂在LS-SCLC和ES-SCLC的总生存无显著差异,挑战顺铂优越性的传统观念。

研究设计与样本

  • 基于荷兰癌症登记数据,分析2018–2023年一线铂类治疗的LS-SCLC和ES-SCLC患者,共纳入LS-SCLC 1683例(卡铂1011例[60%],顺铂672例[40%])和ES-SCLC 3668例(卡铂3002例[82%],顺铂666例[18%])。
  • 总生存采用单变量和多变量分析;3–5级治疗相关不良事件在三家医院研究。

主要发现

  • 疫情期间卡铂季度使用率在LS-SCLC达81%、ES-SCLC达90%。
  • LS-SCLC单变量分析卡铂中位OS 17.9个月 vs 顺铂26.3个月(HR 1.48,95%CI 1.31-1.68,p<0.001)。
  • ES-SCLC单变量分析卡铂中位OS 8.0个月 vs 顺铂9.3个月(HR 1.19,95%CI 1.09-1.30,p<0.001)。
  • 多变量校正后LS-SCLC无显著OS差异(HR 1.06,95%CI 0.90-1.25,p=0.463),ES-SCLC亦无显著差异(HR 1.01,95%CI 0.92-1.12,p=0.785)。
  • 卡铂血液学毒性更高,顺铂非血液学毒性更多。

关键数值与推荐

  • LS-SCLC多变量模型校正混杂因素:体能状态(PS)、年龄、性别和放化疗类型。
  • ES-SCLC多变量模型校正混杂因素:PS、年龄、性别、分期和肝转移。

临床怎么用

  • 在SCLC一线治疗中,卡铂可作为顺铂的合理替代,尤其考虑毒性谱和实际便利性。
  • 选择铂类时应综合评估患者体能状态、年龄、分期、肝转移及放化疗类型等混杂因素。

局限性

  • 3–5级治疗相关不良事件仅在三家医院研究,样本来源有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guidelines recommend cisplatin as the preferred platinum agent in the first-line treatment for small cell lung cancer (SCLC), especially limited-stage disease (LS-SCLC). However, during the COVID-19 pandemic, carboplatin use likely increased due to logistical advantages. We evaluated the pandemic's impact on platinum agent utilization in the Netherlands and compared overall survival (OS) and safety between cisplatin and carboplatin. METHODS: Using Netherlands Cancer Registry data, first-line platinum-based treatments for LS-SCLC and extensive-stage SCLC (ES-SCLC) between 2018 and 2023 were analyzed. OS was evaluated using univariable and multivariable analyses. Grades 3-5 treatment-related adverse events were studied in three hospitals. FINDINGS: Overall, 1683 LS-SCLC (carboplatin, N = 1011[60 %]; cisplatin, N = 672[40 %]) and 3668 ES-SCLC (carboplatin, N = 3002[82 %]; cisplatin, N = 666[18 %]) patients were included. During the pandemic, quarterly usage rates of carboplatin reached up to 81 % and 90 % in LS-SCLC and ES-SCLC, respectively. In LS-SCLC, univariable analysis showed significantly shorter median OS with carboplatin compared to cisplatin (17.9m vs. 26.3m; HR, 1.48; 95 %CI, 1.31-1.68; p < 0.001). Similar findings were observed in ES-SCLC (8.0m vs. 9.3m; HR, 1.19; 95 %CI, 1.09-1.30; p < 0.001). However, multivariable analyses, after adjusting for confounders, showed no significant OS differences in either LS-SCLC (HR, 1.06; 95 %CI, 0.90-1.25; p = 0.463) or ES-SCLC (HR, 1.01; 95 %CI, 0.92-1.12; p = 0.785). Confounders were performance status (PS), age, sex, and chemoradiotherapy type for LS-SCLC, and PS, age, sex, stage, and liver metastases for ES-SCLC. Hematologic toxicity was higher with carboplatin, while cisplatin led to more nonhematologic toxicity. INTERPRETATION: These findings challenge the long-standing belief of cisplatin's superiority and support the adoption of carboplatin in SCLC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Houda I, Naves D, Ulas EB, et al. Survival outcomes with carboplatin versus cisplatin and the impact of COVID-19 on platinum choice: A nationwide Netherlands registry study in small cell lung cancer patients (CACIS). Eur J Cancer. 2025. PMID: 41061426. doi:10.1016/j.ejca.2025.116042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。